The Complexities of Managing Patients with Sleep-Wake Disorders: The Need to Treat the Whole Patient
neuroscienceCME Live and On Demand
Premiere Date: Wednesday, September 2, 2009This activity offers CE credit for:
- Physicians (ACCME/AMA PRA Category 1)
- Nurses (CNE)
- Pharmacists (ACPE)
- Psychologists (APA)
- Social Workers (NASW)
- Certified Case Managers (CCMC)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Thursday, September 2, 2010
Note: Credit Is No Longer Available
 | Thomas Roth, PhD (Moderator) Chief, Division Head Sleep Disorders and Research Center Henry Ford Hospital Detroit, MI |
 | Larry Culpepper, MD, MPH Professor of Family Medicine Boston University School of Medicine Staff Physician, Family Medicine Boston Medical Center Boston, MA |
 | Phyllis C. Zee, MD, PhD Director, Center for Circadian and Sleep Medicine Chief of Sleep Medicine in the Department of Neurology Benjamin and Virginia T. Boshes Professor of Neurology Professor of Neurology (Sleep Medicine) Northwestern University Feinberg School of Medicine Chicago, IL |
Patients with sleep-wake disorders such as obstructive sleep apnea, shift work sleep disorder, and jet lag disorder are
complex in their presentation and pose significant therapeutic challenges. Sleep-wake disorder patients often present
with the symptom of excessive sleepiness and although highly prevalent and detrimental to the patient, society, and
the healthcare system, excessive sleepiness remains under-recognized as well as not appropriately managed. Both
patients and physicians often view sleepiness as a normal phenomenon; patients may not mention it, and if they do,
physicians may not view it as a serious symptom in need of further attention. In part, the difficulty may arise from the
fact that patients often do not complain of excessive sleepiness but instead may use terms like fatigue, tired, and lack of
energy that may not raise clinical concern or may lead to misdiagnosis (e.g., depression) and inappropriate treatment.
In some cases, patients may report problems with their memory or concentration, or automobile crashes. In fact,
patients often do not mention anything at all unless some consequence has ensued, like an automobile crash. In this
neuroscienceCME Live and On Demand activity, the expert faculty will examine the challenges of sleep-wake disorders
from the primary care and sleep specialist perspective with the goal of providing tools for improved recognition,
assessment, and coordinated care of the whole patient.
- Rakel RE. Clinical and societal consequences of obstructive sleep apnea and excessive daytime sleepiness. Postgrad Med 2009;121:86-95.
To identify and accurately diagnose sleep-wake disorders and improve the continuum of care between primary care and sleep specialists.
At the end of this CE activity, participants should be able to:
- Increase the percentage of patient visits during which sleep-wake function is evaluated with a screening tool to improve the recognition of sleep-wake disorder symptoms.
- Utilize diagnostic tools and instruments to improve the accuracy in the differential diagnosis of disorders with excessive sleepiness including obstructive sleep apnea, narcolepsy, and circadian rhythm sleep disorders such as shift work sleep disorder and jet lag disorder in patients.
- Integrate primary care providers and sleep specialists into patient care to improve ongoing communication among providers regarding the optimal management of patients with sleep-wake disorders.
The following learning objectives pertain only to those requesting CNE or CPE credit:
- Evaluate available screening tools to improve the recognition of sleep-wake disorder symptoms.
- Identify diagnostic tools and instruments to improve the accuracy of differential diagnosis of comorbid sleep-wake disorders including obstructive sleep apnea and circadian rhythm sleep disorders such as shift work sleep disorder and jet lag disorder in patients.
- Identify a local network of primary care providers and sleep specialists into patient care to improve ongoing communication among providers regarding the overall management of patients with sleep-wake disorders.
Physicians, physician assistants, nurse practitioners, nurses, psychologists, social workers, certified case managers, pharmacists, and other healthcare professionals interested in sleep-wake medicine.
CME Credit (Physicians):
CME Outfitters, LLC, is accredited
by the Accreditation Council for Continuing
Medical Education to provide continuing
medical education for physicians.
CME Outfitters, LLC, designates this educational activity for
a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians
should only claim credit commensurate with the extent of
their participation in the activity.
CNE Credit (Nurses):
This continuing nursing education activity was approved by the New York State Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation.
It has been assigned approval code 7ZDSU9-10. 1.0 contact
hours will be awarded upon successful completion.
CEP Credit (Psychologists):
CME Outfitters is approved
by the American Psychological Association to sponsor
continuing education for psychologists. CME Outfitters
maintains responsibility for this program and its content.
(1.0 CE credits)
NASW Credit (Social Workers):
This program was approved
by the National Association of Social Workers (provider
#886407722) for 1 continuing education contact hour.
CCMC Credit (Certified Case Managers):
This program
has been approved for 1 hour by the Commission for Case
Manager Certification (CCMC).
CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited
by the Accreditation Council for Pharmacy Education
as a provider of continuing pharmacy education.
1.0 contact hours (0.1 CEUs)
Universal Program Number:
376-000-09-020-L01-P (live presentation)
376-000-09-020-H01-P (recorded programs)
Activity Type: knowledge-based
Post-tests, credit request forms, and activity evaluations can be
completed online at www.neuroscienceCME.com (click on the
Testing/Certification link under the Activities tab—requires free
account activation), and participants can print their certificate
or statement of credit immediately (70% pass rate required).
Otherwise, participants should fully complete and return both
the credit request form and activity evaluation located within the
course guide for this activity. A certificate or statement of credit
will be mailed within 4–6 weeks to all who successfully complete
these requirements. This website supports all browsers except
Internet Explorer for Mac. For complete technical requirements
and privacy policy, visit www.neuroscienceCME.com/technical.asp.
Disclosure Declaration
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Roth has disclosed that he receives grant support from Aventis, Cephalon, Inc., GlaxoSmithKline, Neurocrine Biosciences, Inc., Pfizer, Inc., Sanofi-aventis, Schering-Plough Corporation, Sepracor, Inc., Samaxon Pharmaceuticals, Inc., Syrex, Takeda Pharmaceuticals North America, Inc., TransOral Pharmaceuticals, Inc., Wyeth Pharmaceuticals, and XenoPort, Inc. He serves as a consultant to Abbott Laboratories, Acadia Pharmaceuticals Inc., Acoglix, Acorda Therapeutics, Actelion, Addrenex Pharmaceuticals, Inc., Alchemers, ALZA Corporation, Ancil, Arena Pharmaceuticals, AstraZeneca Pharmaceuticals LP, Aventis, AVER, Bayer, Bristol-Myers Squibb Company, BTG, Cephalon, Inc., Cypress Pharmaceutical, Inc., Dove Pharmaceuticals, Eisai Pharmaceuticals, Elan Pharmaceuticals, Inc., Eli Lilly and Company, Evotec Inc., Forest Laboratories, Inc., GlaxoSmithKline, Hypnion Inc., IMPAX Laboratories, Inc., Intec Pharma, Intra-Cellular, Jazz Pharmaceuticals, Johnson & Johnson Pharmaceutical Research & Development, L.L.C., King Pharmaceuticals, Inc.; H. Lundbeck A/S; McNeil; MediciNova, Inc.; Merck & Co., Inc.; Neurim Pharmaceuticals; Neurocrine Biosciences, Inc.; Neurogen Corporation, Novartis Pharmaceuticals Corporation, Orexo AB, Organon International, Otsuka America Pharmaceutical, Inc., Prestwick Pharmaceuticals, Inc., Proctor & Gamble, Pfizer, Inc., Purdue Pharma L.P., Resteva, Roche, Sanofi-aventis, Schering-Plough Corporation, Sepracor, Inc., Servier, Shire Pharmaceuticals, Samaxon Pharmaceuticals, Inc., Syrex, Takeda Pharmaceuticals North America, Inc., TransOral Pharmaceuticals, Inc., VANDA Pharmaceuticals, VivoMetrics, Wyeth Pharmaceuticals, Yamanouchi Pharma America, Inc., and XenoPort, Inc. He is on the speakers bureau for Cephalon, Inc., Sanofi-aventis, and Takeda Pharmaceuticals North America, Inc.
Dr. Culpepper has disclosed that he serves as a consultant to AstraZeneca Pharmaceuticals LP, Forest Laboratories, Inc., Eli Lilly and Company, Pfizer, Inc., Somaxon Pharmaceuticals, Inc., Takeda Pharmaceuticals North America, Inc., and Wyeth Pharmaceuticals. He is on the speakers bureau for Forest Laboratories, Inc. and Wyeth Pharmaceuticals.
Dr. Zee has disclosed that she receives grant support from Takeda Pharmaceuticals North America, Inc. She serves as a consultant to Cephalon, Inc., Philips, Sanofi-aventis, and Takeda Pharmaceuticals North America, Inc. She is a stock shareholder of Teva Pharmaceuticals USA.
Unlabeled Use Disclosure
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
CME Outfitters, LLC, the faculty, and Cephalon, Inc., do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).
TV-060-090209-05
